Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Test_Release_V6.14.1 (Do Not Make Change)  

Pityful a rethoric question ran over her cheek, then she continued her way. On her way she met a copy. The copy warned the Little Blind Text, that where it came from it would have been rewritten a thousand times and everything that was left from its origin would be …

  • 0 views
  • 05 Feb, 2025
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation

This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.

measurable disease
stage iv non-small cell lung cancer
small cell lung cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced c-MET-positive Non-Small Cell Lung Cancer

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 15 patients Phase (globally): Approximately 90 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)

  • 0 views
  • 16 Feb, 2024
  • 1 location
Phase Study of the HS-10241 in Patients With Advanced Solid Tumors

HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth.

solid tumor
bilateral salpingectomy
melanoma
ct scan
vomit
  • 0 views
  • 05 Aug, 2020
Effects of Autogenic and Reciprocal Inhibition Techniques With Conventional Therapy in Mechanical Neck Pain

Group 1 will receive Autogenic Inhibition muscle energy technique (MET) with conventional therapy and Group 2 will receive Reciprocal inhibition MET with conventional therapy. A total of 12 sessions will be provided.

  • 0 views
  • 16 Sep, 2021
  • 1 location
Group Activities to Support Addiction Recovery

Inclusion criteria consist of being 19 years of age or older and having met criteria for a substance use disorder within the past five years. Additional inclusion criteria for participants in arm A include being in a residential addiction treatment program at CenterPointe or the Bridge.

  • 0 views
  • 25 Jul, 2025
  • 1 location
A Phase I Study of SB Cell for the Enhanced Osseointegration of Guided Bone Regeneration in Implant Surgery

This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to enhance osseointegration of GBR in patients undergoing dental implant surgery.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Iatrogenic Atrial Septal Defect Study (iASD)

This is an open-label, randomized, controlled trial of iatrogenic atrial septal defect closure with the an atrial septal occluder versus usual care observation in patients post-mitral valve intervention requiring large bore transspetal access.

closure of atrial septal defect
atrial septal defect
regurgitation
septal defect
mitral regurgitation
  • 0 views
  • 16 Feb, 2024
  • 1 location
Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety and efficacy of GCSF in each of the 2 groups of newly diagnosed BA patients: KBA (i.e., Kasai-operated) or NoK (i.e., patients who …

direct bilirubin
serum direct bilirubin
biliary atresia
filgrastim
g-csf
  • 0 views
  • 16 Feb, 2024
  • 3 locations
A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR). This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin.

  • 0 views
  • 16 Feb, 2024
  • 8 locations